Expansion of HIV/AIDS, STI and TB Laboratory Activities in the Namibia Institute of Pathology (NIP), Ltd under the Presidentмs Emergency Plan for AIDS Relief (PEPFAR)

Post Date

January 4th 2016

Application Due Date

February 29th 2016

Funding Opportunity Number

CDC-RFA-PS09-955SUPP16

CFDA Number(s)

93.067

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Health

Number of Awards

1

Eligibility Categories

Other

Eligible applicants that can apply for this funding opportunity appear below: ╢ Namibia Institute of Pathology

Funding

• Estimated Total Funding:

  $2060747

• Award Range:

  $0 - $0

Grant Description

Eligible applicants that can apply for this funding opportunity appear below: ╢ Namibia Institute of Pathology Under the leadership of the U.S. Global AIDS Coordinator, as part of the President's Emergency Plan, the U.S. Department of Health and Human Servicesм Centers for Disease Control and Prevention (HHS/CDC) works with host countries and other key partners to assess the needs of each country and design a customized program of assistance that fits within the host nation's strategic plan. HHS/CDC focuses on two or three major program areas in each country. Goals and priorities include the following: ╢ Achieving primary prevention of HIV infection through activities such as expanding confidential counseling and testing programs and building programs to reduce mother-tochild transmission; ╢ Improving the care and treatment of HIV/AIDS, sexually transmitted infections (STIs) and related opportunistic infections by improving STI management; enhancing the care and treatment of opportunistic infections, including tuberculosis (TB); and initiating programs to provide anti-retroviral therapy (ART); and ╢ Strengthening the capacity of countries to collect and use surveillance data and manage national HIV/AIDS programs by expanding HIV/STI/TB surveillance programs and strengthening laboratory support for surveillance, diagnosis, treatment, disease monitoring and HIV screening for blood safety. The purpose of the program is to improve national surveillance for HIV infection, sexually transmitted infections (STIs), and tuberculosis (TB) as well as to expand the capacity of the Namibia Institute of Pathology (NIP) to provide services for diagnosing and managing these diseases and others related to HIV infection and transmission in Namibia. Additionally, through special initiative funding, the grantee will scale-up HIV/AIDS treatment services in priority regions in Namibia with high HIV disease burden. The U.S. Government seeks to reduce the impact of HIV/AIDS in specific countries within sub- Saharan Africa, Asia, and the Americas through the Presidentмs Emergency Plan for AIDS Relief (PEPFAR). Through PEPFAR, CDCмs Global AIDS Program (GAP) will continue to work with host countries to strengthen capacity and expand activities in the areas of: (1) primary HIV prevention; (2) HIV care, support and treatment; and (3) capacity and infrastructure development, especially for surveillance and pre- and in-service training. Targeted countries represent those with the most severe epidemics where the potential for impact is greatest and where U.S. Government agencies are already active. Namibia is one of these targeted countries. To carry out its activities in these countries, CDC is working in a collaborative manner with national governments and other agencies to develop programs of assistance to address the HIV/AIDS epidemic. CDCмs program of assistance to Namibia focuses on several areas of national priority including scaling up of promising strategies for HIV prevention, care and treatment.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  Centers for Disease Control and Prevention

• Agency Contact:

  Rhonda D. Latimer
  Grants Management Specialist
  Office of Grants Services (OGS)
  Office of Financial Resources (OFR)
  Office of the Chief Operating Officer (OCOO)
  Centers for Disease Control and Prevention (CDC)
  RDLatimer@cdc.gov | 770-488-1647 office

• Agency Mailing Address:

  RDLatimer@cdc.gov

• Agency Email Address:

  RDLatimer@cdc.gov